-
MMAF sodium
- names:
MMAF sodium
- CAS号:
1799706-65-2
MDL Number: - MF(分子式): C39H64N5NaO8 MW(分子量): 753.94
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000926-5mg | 5mg | 99.73% | ¥ 3915.00 | ¥ 3915.00 | 2-3天 | ¥ 0.00 | ||
| YZM000926-2mg | 2mg | 99.73% | ¥ 1950.00 | ¥ 1950.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | MMAF sodium |
| CAS号 | 1799706-65-2 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C39H64N5NaO8 |
| 分子量 Molecular Weight | 753.94 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度≥ 200 mg/mL(265.27 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性状 | |
| 储藏条件 Storage conditions | 4°C, stored under nitrogen * In solvent : -80°C, 6 months月; -20°C, 1 month月 (stored under nitrogen) |
| 产品说明 | |
| Introduction | MMAF sodium (Monomethylauristatin F sodium) is a potenttubulin polymerizationinhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibodyrug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGND19A[2][3]. |
| Application1 | |
| Application2 | |
| Application3 |
MMAF sodium (Monomethylauristatin F sodium) 是一种有效的微管蛋白聚合 (tubulin polymerization) 抑制剂,用作抗肿瘤药物。MMAF sodium (Monomethylauristatin F sodium) 广泛用作抗体-药物偶联物 (ADCs) 的细胞毒性成分,如Vorsetuzumab mafodotin 和 SGN-CD19A。MMAF sodium (Monomethylauristatin F sodium) is a potenttubulin polymerizationinhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A[1][2][3].
【1】.Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.
【2】.Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.
【3】.Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.
【4】.Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.
【2】.Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.
【3】.Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.
【4】.Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


